Review
Biochemistry & Molecular Biology
Yasushi Sato, Koichi Okamoto, Tomoyuki Kawaguchi, Fumika Nakamura, Hiroshi Miyamoto, Tetsuji Takayama
Summary: Neoadjuvant chemotherapy (NAC) is an effective therapeutic option for locally advanced gastric cancer (LAGC), but its therapeutic effect is unpredictable due to tumor heterogeneity and a lack of predictive biomarkers. Researchers are focusing on biomarkers such as metabolic enzymes, nucleotide excision repair, and microsatellite instability, as well as noninvasive liquid biopsy detection methods such as miRNA and exosome detection, to guide the choice of preoperative treatment.
Article
Medicine, General & Internal
Re- Chin, Ebunoluwa E. Otegbeye, Kylie H. Kang, Su-Hsin Chang, Scott McHenry, Amit Roy, William C. Chapman, Lauren E. Henke, Shahed N. Badiyan, Katrina Pedersen, Benjamin R. Tan, Sean C. Glasgow, Matthew G. Mutch, Pamela P. Samson, Hyun Kim
Summary: This study compared the cost-effectiveness of SCRT-TNT and LCCRT in the treatment of patients with locally advanced rectal cancer. The results showed that SCRT-TNT had lower costs and improved quality-adjusted life years (QALYs) compared to conventional LCCRT.
Article
Oncology
Alina Desiree Sando, Reidun Fougner, Elin Synnove Royset, Hong Yan Dai, Jon Erik Gronbech, Erling Audun Bringeland
Summary: Evaluation of response following neoadjuvant chemotherapy (NAC) in gastric cancer has been widely debated. The aim of this study was to investigate downsizing and downstaging as methods of response evaluation. The findings suggest that comparing the baseline radiological CT stage to the pathological stage following NAC is a useful method for stratifying patients based on their long-term survival rates.
Review
Oncology
Jiuzhou Chen, Yaru Guo, Miao Fang, Yan Yuan, Youqi Zhu, Yong Xin, Longzhen Zhang
Summary: This study evaluated the clinical curative effects and toxicity of neoadjuvant chemoradiotherapy compared to neoadjuvant chemotherapy for resectable gastric cancer. The results showed that neoadjuvant chemoradiotherapy had better efficacy, improved survival rates, and fewer adverse effects compared to neoadjuvant chemotherapy. Therefore, neoadjuvant chemoradiotherapy has great potential as an effective therapy for resectable gastric cancers.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Lorenzo Gervaso, Stefania Pellicori, Chiara A. Cella, Vincenzo Bagnardi, Florian Lordick, Nicola Fazio
Summary: The study highlights the importance of identifying molecular biomarkers in patients undergoing neoadjuvant chemotherapy for locally advanced resectable gastric or esophagogastric junction cancer. Despite improvements in prognosis, relapse-related death remains a major challenge, and further research is needed to understand which patients will benefit from peri-operative treatment. Biomarkers such as HER2, MSI, and EBV have shown promise but require more methodologically sound clinical trials to guide treatment choices effectively.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2021)
Review
Oncology
M. Usman Ahmad, Christopher Javadi, George A. Poultsides
Summary: Neoadjuvant and/or perioperative therapy has emerged as a treatment tool to improve patient selection and locoregional control for resectable proximal gastric, gastroesophageal junction, and distal esophageal cancer. Treatment recommendations differ based on histologic type and tumor location. Neoadjuvant chemoradiation with concurrent taxane- or fluoropyrimidine-based chemotherapy has shown efficacy for both adenocarcinoma and squamous cell carcinoma of the distal esophagus and gastroesophageal junction.
Article
Medicine, General & Internal
Eric Anderson, Alexis LeVee, Sungjin Kim, Katelyn Atkins, Michelle Guan, Veronica Placencio-Hickok, Natalie Moshayedi, Andrew Hendifar, Arsen Osipov, Alexandra Gangi, Miguel Burch, Kevin Waters, May Cho, Samuel Klempner, Joseph Chao, Mitchell Kamrava, Jun Gong
Summary: The study reveals that neoadjuvant chemoradiation (nCRT) is associated with the highest rate of pathologic complete response, while neoadjuvant and adjuvant chemotherapy (CTTU) is associated with the best overall survival.
Article
Oncology
Gregory P. Botta, Tridu R. Huynh, Samantha R. Spierling-Bagsic, Alexander Agelidis, Randolph Schaffer, Ray Lin, Darren Sigal
Summary: Patients with borderline-resectable and locally-advanced pancreatic cancer who underwent surgical resection after receiving neoadjuvant chemotherapy alone had better treatment outcomes compared to those requiring combination chemotherapy and radiation.
Article
Medicine, General & Internal
Patrick M. Forde, Jonathan Spicer, Shun Lu, Mariano Provencio, Tetsuya Mitsudomi, Mark M. Awad, Enriqueta Felip, Stephen R. Broderick, Julie R. Brahmer, Scott J. Swanson, Keith Kerr, Changli Wang, Tudor-Eliade Ciuleanu, Gene B. Saylors, Fumihiro Tanaka, Hiroyuki Ito, Ke-Neng Chen, Moishe Liberman, Everett E. Vokes, Janis M. Taube, Cecile Dorange, Junliang Cai, Joseph Fiore, Anthony Jarkowski, David Balli, Mark Sausen, Dimple Pandya, Christophe Y. Calvet, Nicolas Girard
Summary: In patients with resectable non-small-cell lung cancer (NSCLC), neoadjuvant nivolumab plus chemotherapy resulted in significantly longer event-free survival and a higher percentage of patients with a pathological complete response than chemotherapy alone.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Review
Immunology
Qing Li, Ting Liu, Zhenyu Ding
Summary: Esophageal cancer is one of the most common cancers worldwide, especially in China. Current treatment methods have limited efficacy, necessitating the exploration of new treatment strategies. Immunotherapy has emerged as a promising approach and has been shown to significantly improve survival rates in cancer patients. Combining chemotherapy and/or radiotherapy with immunotherapy may have a synergistic antitumor effect.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Aurelien Lambert, Lilian Schwarz, Michel Ducreux, Thierry Conroy
Summary: Only 10-20% of patients with resectable pancreatic adenocarcinoma have potentially resectable disease. After surgical extirpation of tumors, up to 80% of patients will develop cancer recurrence, and adjuvant chemotherapy is the best strategy to improve overall survival. Neoadjuvant treatment shows some promising results but still requires further investigation to be validated.
Article
Oncology
Jin He, Richard D. Schulick, Marco Del Chiaro
Summary: The definition of BRPC should consider biological and conditional dimensions in addition to the anatomic relationship between the tumor and vessels. Neoadjuvant chemotherapy and surgery are associated with improved outcomes of BRPC.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Alina Desiree Sando, Reidun Fougner, Jon Erik Gronbech, Erling Audun Bringeland
Summary: The value of routine CT-scan following neoadjuvant chemotherapy in gastric cancer is limited, with poor accuracy in staging compared to final pathologic stage. Radiologic downstaging as a measure of response evaluation is unreliable and unable to discriminate long-term survival rates based on response mode.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2021)
Article
Medicine, Research & Experimental
Pengfei Su, Lin Jiang, Yingjing Zhang, Tian Yu, Hongyun Huang, Moxi Chen, Can Cao, Weiming Kang, Yuqin Liu, Jianchun Yu
Summary: This study compared the efficacy of perioperative chemotherapy (PEC) and adjuvant chemotherapy (AC) in resectable locally advanced gastric cancer (LAGC) patients. The results showed that PEC led to a higher R0 resection rate and tumor downstage, without increasing postoperative complications or grade 3/4 adverse events related to AC. PEC was independently associated with better overall survival (OS) and disease-free survival (DFS) in resectable LAGC.
EUROPEAN JOURNAL OF MEDICAL RESEARCH
(2023)
Review
Immunology
Hao Xu, Tengyun Li, Guoyi Shao, Weizhi Wang, Zhongyuan He, Jianghao Xu, Yawei Qian, Hongda Liu, Han Ge, Linjun Wang, Diancai Zhang, Li Yang, Fengyuan Li, Zekuan Xu
Summary: Background: Immunochemotherapy is increasingly used in the treatment of advanced gastric cancer, with PD-1 inhibitors combined with chemotherapy becoming the first-line treatment. However, further studies are needed to assess the efficacy and safety of this treatment regimen in the neoadjuvant phase. Conclusion: Neoadjuvant immunochemotherapy appears to be a promising strategy for the treatment of advanced gastric cancer, but more randomized controlled trials are needed to confirm its effectiveness and safety.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Satoshi Teramae, Naoki Muguruma, Koichi Okamoto, Kumiko Oseto, Ryutaro Nishikawa, Takayuki Tanoue, Keiji Hirata, Shunichi Yanai, Takayuki Matsumoto, Seiji Shimizu, Jun Miwa, Yu Sasaki, Kazuo Yashima, Hiroyuki Ohnuma, Yasushi Sato, Yoshitaka Kitayama, Yoshio Ohda, Atsushi Yamauchi, Yoji Sanomura, Kumiko Tanaka, Yoshiaki Kubo, Hideki Ishikawa, Yoshimi Bando, Tomoko Sonoda, Tetsuji Takayama
Summary: This study provides important clinical characteristics of Cowden syndrome (CS) in Japanese patients. The results indicate that Japanese CS patients, especially female patients and those with C2 domain variant, have a higher risk of cancer.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2022)
Review
Multidisciplinary Sciences
Yoshiro Niitsu, Yasushi Sato, Tetsuji Takayama
Summary: GSTP1, a glutathione-S transferase isozyme, is highly expressed in malignant tissues and serves as a tumor marker and a refractory factor against certain types of anticancer drugs. Recent studies have also identified its chaperone activity in regulating intracellular protein function.
PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES
(2022)
Article
Oncology
Tetsu Tomonari, Joji Tani, Yasushi Sato, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, Akihiro Morishita, Koichi Okamoto, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma, Tsutomu Masaki, Tetsuji Takayama
Summary: This study analyzed the association between modified albumin-bilirubin (mALBI) grade and therapeutic efficacy of atezolizumab plus bevacizumab (Atezo+Bev) treatment for unresectable hepatocellular carcinoma (u-HCC). The results showed that patients with mALBI 1+2a had better treatment response and longer progression-free survival.
Article
Oncology
Beibei Ma, Hiroyuki Ueda, Koichi Okamoto, Masahiro Bando, Shota Fujimoto, Yasuyuki Okada, Tomoyuki Kawaguchi, Hironori Wada, Hiroshi Miyamoto, Mitsuo Shimada, Yasushi Sato, Tetsuji Takayama
Summary: This study compares patient-derived organoids from left- and right-sided colorectal cancers (CRCs) and finds that right-sided CRCs have higher cell proliferation and invasion capability. The study also suggests that in right-sided CRCs, TIMP1 is overexpressed and promotes cell proliferation and invasion through the TIMP1/FAK/Akt pathway, leading to a poor prognosis.
Article
Multidisciplinary Sciences
Masahiro Sogabe, Toshiya Okahisa, Takeshi Kurihara, Miwako Kagawa, Hiroyuki Ueda, Tomoyuki Kawaguchi, Akira Fukuya, Kaizo Kagemoto, Hironori Tanaka, Yoshifumi Kida, Tetsu Tomonari, Tatsuya Taniguchi, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Masahiko Nakasono, Tetsuji Takayama
Summary: This study found that male patients with MAFLD had higher prevalence of metabolic dysregulation, ratio of visceral fat area to subcutaneous fat area, and noninvasive liver fibrosis scores compared to those with NAFLD. However, these differences were not significant in female patients. Furthermore, among male patients, those in the MAFLD group with alcohol consumption exceeding 70g/week had significantly higher noninvasive liver fibrosis scores compared to the NAFLD group.
SCIENTIFIC REPORTS
(2022)
Article
Nutrition & Dietetics
Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Hiroyuki Ueda, Kaizo Kagemoto, Hironori Tanaka, Yoshifumi Kida, Tetsu Tomonari, Tatsuya Taniguchi, Hiroshi Miyamoto, Yasushi Sato, Masahiko Nakasono, Tetsuji Takayama
Summary: This observational study investigated the influence of alcohol consumption on the development of erosive esophagitis (EE) in both sexes. The study found that the impact of alcohol consumption on EE development differed between men and women, and there was an association between drinking and EE development in individuals under the age of 50. It is recommended that individuals under the age of 50 should avoid alcohol consumption to prevent the development of EE, and daily drinkers should be assessed for EE development.
Article
Gastroenterology & Hepatology
Megumi Yamasaki, Yasushi Sato, Koichi Okamoto, Akira Fukuya, Tomoyuki Kawaguchi, Kazuyoshi Noda, Kaizo Kagemoto, Yasuhiro Mitsui, Hiroshi Miyamoto, Tetsuji Takayama
Summary: Induction chemotherapy with DCS, followed by CRT with S-1, may be beneficial for patients with locally advanced ASCC.
CLINICAL JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Nutrition & Dietetics
Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Hiroyuki Ueda, Kaizo Kagemoto, Hironori Tanaka, Yoshifumi Kida, Tetsu Tomonari, Tatsuya Taniguchi, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Masahiko Nakasono, Tetsuji Takayama
Summary: This observational cohort study found that alcohol consumption did not have a significant protective effect against newly developed MAFLD in both sexes, and instead, a weekly alcohol consumption ≥140 g was a risk factor for newly developed MAFLD in women. Several non-invasive fibrosis scores were significantly associated with the quantity of alcohol consumption in patients with newly developed MAFLD.
CLINICAL NUTRITION
(2023)
Review
Medicine, General & Internal
Yasushi Sato, Koichi Okamoto, Yoshifumi Kida, Yasuhiro Mitsui, Yutaka Kawano, Masahiro Sogabe, Hiroshi Miyamoto, Tetsuji Takayama
Summary: Gastric cancer (GC) is a challenging cancer, but recent advances in molecular-targeted agents and immunotherapy have improved prognosis. HER2 expression is important in first-line chemotherapy for advanced GC, and the addition of trastuzumab has extended overall survival. For HER2-negative GC, the combination of nivolumab and a cytotoxic agent has shown promise. New treatments for advanced GC include ramucirumab, trifluridine/tipiracil, and trastuzumab deruxtecan. Combining immunotherapy and molecular-targeted agents is an exciting prospect. Understanding biomarkers and selecting optimal therapies is crucial. In resectable disease, differences in lymphadenectomy between Eastern and Western countries lead to different standard treatments: neoadjuvant and adjuvant therapy.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Gastroenterology & Hepatology
Tetsu Tomonari, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, Masahiro Sogabe, Yutaka Kawano, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Tetsuji Takayama
Summary: The efficacy of LEN-TACE in unresectable hepatocellular carcinoma (HCC) refractory to LEN therapy is demonstrated in a case report. The patient had multiple HCCs and was initially treated with TACE, but developed resistance to it and subsequent molecular-targeted agents (MTA). LEN-TACE was attempted as salvage therapy and showed significant reduction in tumor markers and complete response according to RECIST guidelines. LEN-TACE may be a last-line treatment option for unresectable advanced HCC refractory to LEN therapy.
CLINICAL JOURNAL OF GASTROENTEROLOGY
(2023)
Review
Medicine, General & Internal
Yasushi Sato, Koichi Okamoto, Yutaka Kawano, Akinari Kasai, Tomoyuki Kawaguchi, Tamotsu Sagawa, Masahiro Sogabe, Hiroshi Miyamoto, Tetsuji Takayama
Summary: Gastric cancer's heterogeneity makes it difficult to demonstrate treatment efficacy, but efforts have been made to identify molecular biomarkers to better understand this heterogeneity and develop targeted therapies. HER2 overexpression, HER2/neu amplification, MSI-H, and PD-L1+ are predictive biomarkers in gastric cancer, and clinical trials have shown the efficacy of targeted therapies. Enrichment design clinical trials have also demonstrated efficacy in unresectable advanced gastric cancer. Continuous validation and introduction of promising biomarkers into clinical practice are essential for optimal treatment selection and improved patient outcomes.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
Tetsu Tomonari, Joji Tani, Yasushi Sato, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, Yutaka Kawano, Asahiro Morishita, Koichi Okamoto, Masahiro Sogabe, Hiroshi Miyamoto, Tsutomu Masaki, Tetsuji Takayama
Summary: This retrospective study analyzed the treatment outcomes of lenvatinib and atezolizumab + bevacizumab in 244 patients with unresectable hepatocellular carcinoma (HCC). The study found that patients who underwent conversion therapy had significantly higher rates of downstaging and longer overall survival compared to those receiving chemotherapy alone. Patients with mALBI 1+2a and BCLC-B stage were more likely to achieve downstaging through conversion therapy.
Article
Gastroenterology & Hepatology
Taku Takahashi, Yasushi Sato, Takanori Kashihara, Yoshihiro Miyata, Yasuteru Fujino, Yasuhiro Mitsui, Koichi Okamoto, Hiroshi Miyamoto, Yasuhiko Nishioka, Tetsuji Takayama
Summary: Gastric antral vascular ectasia (GAVE) is a rare cause of gastrointestinal bleeding. However, its association with nintedanib use, antifibrotic therapy for idiopathic pulmonary fibrosis (IPF), has not been reported. We present 2 cases of GAVE that were presumed to be secondary to nintedanib use in patients with IPF. Both patients experienced anemia, one of which had hematemesis. GAVE diagnosis was confirmed by upper gastrointestinal endoscopy. Moreover, successful treatment was achieved with endoscopic argon plasma coagulation. These cases highlight the importance of considering GAVE as a potential cause of anemia and upper gastrointestinal bleeding in patients with IPF receiving nintedanib.
ACG CASE REPORTS JOURNAL
(2023)
Review
Medicine, Research & Experimental
Yasushi Sato, Koichi Okamoto, Hiroshi Miyamoto, Tetsuji Takayama
Summary: Chemotherapy for cancer has greatly improved, but older patients face difficulties due to decreased performance status. Gastrointestinal cancer chemotherapy has made progress with targeted agents and immunotherapy, but evidence for efficacy in older patients is limited.
JOURNAL OF MEDICAL INVESTIGATION
(2022)
Article
Gastroenterology & Hepatology
Kumiko Tanaka, Yasushi Sato, Hideki Ishikawa, Naoki Muguruma, Satoshi Teramae, Yoji Takeuchi, Yasuhiro Mitsui, Koichi Okamoto, Hiroshi Miyamoto, Yoshimi Bando, Tomoko Sonoda, Naoki Ohmiya, Michihiro Mutoh, Tetsuji Takayama
Summary: In this study, capsule endoscopy and balloon-assisted endoscopy were performed on 149 FAP patients, revealing that 26.2% of them had small intestinal adenoma with high-grade dysplasia, and 5.4% had cancer. Spigelman stage was significantly associated with number of jejunal/ileal polyps and their high-grade dysplasia.
TECHNIQUES AND INNOVATIONS IN GASTROINTESTINAL ENDOSCOPY
(2022)